Third, IDH wild-type astrocytomas with TERT promoter mutations, EGFR amplification, and + 7/− 10 chromosome copy number changes need to be further considered in future study to fully elucidate the intratumoral heterogeneity of IDH wild-type GBM according to the WHO CNS5. This evidence concerns the gene EGFR and astrocytoma (excluding glioblastoma).